Brought to you by 
Britannia Pharmaceuticals, Novartis develop migraine therapy
21 Mar 2022
Executive Summary
Drug development company Britannia Pharmaceuticals Ltd. and Novartis Pharmaceuticals UK Ltd. are collaborating to develop Britannia's dihydroergotamine (DHE) nasal powder, a patented formulation the company has been developing since 2001 to treat migraine headaches.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Nasal
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Britannia Pharmaceuticals, Novartis develop migraine therapy
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice